A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants ( ≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)
Condition: Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Interventions: Drug: Asciminib; Drug: Nilotinib Sponsor: Novartis Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Chronic Leukemia | Chronic Myeloid Leukaemia | Leukemia | Nilotinib | Research | Study | Tasigna